Introduction: Liver grafts with limited steatosis are currently used for liver transplantation, but the natural history of graft steatosis is not well known. Project Aims or Questions: This program evaluation aimed at assessing changes of steatosis after liver transplantation. Design: A retrospective chart review was performed assessing presence and severity of steatosis in the liver explant and in time zero donor graft biopsies carried out at the time-point of liver transplantation on histopathology and on imaging one year thereafter in 30 well characterized patients. Results: Ten patients (33%) showed steatosis on explant. Time zero biopsy revealed steatosis in 18 grafts (60%) and no steatosis in 12 (40%). One year after transplantation, 8 patients (27%) had steatosis and 22 patients (63%) had none. Fourteen patients (47%) showed changes in steatosis: 12 showed resolution and 2 showed de novo steatosis. Explant macrovesicular steatosis was associated with presence of steatosis 1 year after transplantation (binary logistic regression model, p = 0.014), but not macrovesicular steatosis in the donor graft at time-point of transplantation. Conclusion: Resolution of graft steatosis was frequent. Presence of steatosis in the recipient's liver, but not graft steatosis, was a risk factor for steatosis 1 year after transplantation. Factors related to the recipient seem to prevail over donor-related factors in determining the persistence or de novo appearance of steatosis after liver transplantation.
LinaresIHamarMSelznerNSelznerM. Steatosis in liver transplantation: Current limitations and future strategies. Transplantation. 2019;103(1):78-90. doi:10.1097/TP.0000000000002466
2.
CroomeKPMathurAKMaoS, et al.Perioperative and long-term outcomes of utilizing donation after circulatory death liver grafts with macrosteatosis: A multicenter analysis. Am J Transplant. 2020;20(9):2449-2456. doi:10.1111/AJT.15877
3.
KimHLeeKLeeKW, et al.Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transplant. 2014;28(5):521-529. doi:10.1111/ctr.12343
4.
PatelYAImperialJCMuirAJ, et al.Baseline parameters in clinical trials for nonalcoholic steatohepatitis: Recommendations from the liver forum. Gastroenterology. 2017;153(3):621-625.e7. doi:10.1053/j.gastro.2017.07.024.
5.
CaussyCReederSBSirlinCBLoombaR. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68(2):763-772. doi:10.1002/hep.29797
6.
LimanondPRamanSSLassmanC, et al.Macrovesicular hepatic steatosis in living related liver donors: Correlation between CT and histologic findings. Radiology. 2004;230(1):276-280. doi:10.1148/radiol.2301021176
7.
KarlasTPetroffDSassoM, et al.Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022
8.
IdilmanISOzdenizIKarcaaltincabaM. Hepatic steatosis: Etiology, patterns, and quantification. Semin Ultrasound CT MR. 2016;37(6):501-510. doi:10.1053/J.SULT.2016.08.003
9.
ShakedALozaBLVan LoonE, et al.Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes. Nat Med. 2022;28(5):999-1005. doi:10.1038/s41591-022-01758-7
10.
NarayananPMaraKIzzyM, et al.Recurrent or de Novo allograft steatosis and long-term outcomes after liver transplantation. Transplantation. 2019;103(1):e14-e21. doi:10.1097/TP.0000000000002317
11.
NoureddinMChanJLBarradasK, et al. Attribution of nonalcoholic steatohepatitis as an etiology of cirrhosis for clinical trials eligibility: Recommendations from the multi-stakeholder liver forum. Gastroenterology. 2020;159(2):422-427.e1. doi:10.1053/j.gastro.2020.04.039.
